SecBot SecBot
DEFA14A ·Filed Apr 23, 2026

SLDB

Solid Biosciences Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed6mo ago SEC0001193125-26-173684
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the vote outcomes on the share increase and executive compensation, as these could signal management's capital allocation strategy and governance priorities. The recent board reshuffle suggests ongoing governance adjustments worth watching.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.92
T+0 close · Apr 23, 2026 · via day close
Latest settled
+6.82%
T+60 · $8.46
Vs SPY
+1.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 24 $7.92entry
  2. T+1 · 7mo ago −5.30%α −5.47% · $7.50
  3. T+5 · 7mo ago −8.33%α −9.24% · $7.26
  4. T+20 · 6mo ago −17.93%α −21.96% · $6.50
  5. T+60 · 4mo ago +6.82%α +1.74% · $8.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Solid Biosciences is holding its 2026 annual meeting with several key proposals, including the ratification of Ilan Ganot's board appointment, a share increase to 480 million, and advisory votes on executive compensation. This follows a recent board reshuffle where Ganot was reappointed to a different class, indicating ongoing governance adjustments.

Key Financial Metrics

Vote
director election
Meeting
2026-06-10

Key Facts

  • Election of Class II directors Clare Kahn, Adam Stone, and Lynne Sullivan
  • Ratification of Ilan Ganot's appointment to Class I director
  • Ratification of PricewaterhouseCoopers as independent auditor
  • Proposal to increase authorized shares from 240M to 480M
  • Advisory vote on executive compensation

Financial Impact

Potential dilution from share increase from 240M to 480M authorized shares

dilution

Risk Factors

  • Potential shareholder dilution if the share increase is approved and utilized
  • Governance concerns if executive compensation receives significant opposition

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001193125-26-173684
Document: 0001193125-26-173684-index-headers.html0001193125-26-173684
Document: 0001193125-26-173684-index.html0001193125-26-173684
Document: 0001193125-26-173684.txt0001193125-26-173684

Track record

14 reports on SLDB

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +20.77% at T+20 after the Mar 19, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.84 Now $6.48 −5.26% settles Dec 15
  2. Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $7.02 Now $6.48 −7.69% settles Dec 8
  3. Nov 4, 202612d ago Press Release Neutral 4/10 Entry $6.18 Now $6.48 +4.85% settles Dec 4
  4. Aug 6, 202614w ago S-3ASR Neutral 4/10 Entry $8.39 to $10.25 Now $6.48 −22.77% ▲ +22.17% +22.57% vs SPY
  5. May 12, 202626w ago Press Release Bearish 6/10 Entry $7.38 to $7.22 Now $6.48 +12.20% ▲ +2.17% +1.56% vs SPY
  6. May 7, 202627w ago Press Release Bullish 7/10 Entry $7.07 to $6.85 Now $6.48 −8.35% ▼ −3.11% −6.25% vs SPY
  7. Apr 23, 202629w ago DEFA14A Neutral 3/10 Viewing Entry $7.92 to $6.50 Now $6.48 −18.18% ▼ −17.93% −21.96% vs SPY
  8. Apr 10, 202631w ago 8-K Neutral 2/10 Entry $8.39 to $7.68 Now $6.48 −22.77% ▼ −8.46% −16.19% vs SPY
  9. Apr 1, 202632w ago EFFECT Bearish 7/10 Entry $7.38 to $7.05 Now $6.48 +12.20% ▲ +4.47% +14.19% vs SPY
  10. Mar 19, 202634w ago Press Release Bullish 8/10 Entry $7.03 to $8.49 Now $6.48 −7.82% ▲ +20.77% +11.45% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 40m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 23, 2026